Biomea Fusion

Biomea Fusion is a private precision medicine company with the mission to revolutionize drug development and create more effective therapies for cancer patients. The company was founded by a team of experienced drug developers to build a platform for irreversible inhibitors. Biomea Fusion has a development portfolio that targets specific genetic mutations occurring in patient DNA, which translate into key drivers of tumor growth. Biomea’s goal is to rapidly advance these potentially breakthrough drugs through the development process to provide highly impactful treatments for patients in need. The lead program targets the protein-protein interaction between Brain Machine and MLL complexes for the treatment of various tumors.